Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Revenue of Cogent Biosciences, Inc. (COGT)
Revenue in 2023 (TTM): $
According to Cogent Biosciences, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Cogent Biosciences, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-3,588,000 | $-205,860,000 | $-192,410,000 | $-192,410,000 |
| 2022 | $ | $-5,878,000 | $-147,839,000 | $-140,241,000 | $-132,643,000 |
| 2021 | $ | $-147,000 | $-75,404,000 | $-72,273,000 | $-71,806,000 |
| 2020 | $7.87 M | $7.85 M | $-89,692,000 | $-74,808,000 | $-66,451,000 |
| 2019 | $22.5 M | $22.46 M | $-32,178,000 | $-31,833,000 | $-30,273,000 |
| 2018 | $9.73 M | $9.73 M | $-34,684,000 | $-34,532,000 | $-34,532,000 |
| 2017 | $8.36 M | $8.36 M | $-24,981,000 | $-25,492,000 | $-25,492,000 |
| 2016 | $6.36 M | $6.36 M | $-18,240,000 | $-18,124,000 | $-18,124,000 |
| 2015 | $2.99 M | $2.99 M | $-6,413,000 | $-6,592,000 | $-6,592,000 |